z-logo
open-access-imgOpen Access
CPX‐351 (Vyxeos ® ) can cause severe rash in acute myeloid leukemia—A case report
Author(s) -
Urbantat Ruth M.,
Popper Valentin,
Menschel Elisabeth,
Pfeilstöcker Michael,
Forjan Ernst,
Nader Alexander,
Sieghart Catherine R.,
Keil Felix,
Koller Elisabeth
Publication year - 2021
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.3909
Subject(s) - medicine , rash , myeloid leukemia , leukemia , dermatology , immunology
CPX‐351, a promising new agent for patients with treatment‐related and secondary acute myeloid leukemia can lead to a severe whole‐body rash. Although severe side effects are rare, treatment should be carefully monitored at specialized centers.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here